ES2147646T3 - Composiciones para diagnostico, prevencion y tratamiento de la progresion de los tumores. - Google Patents

Composiciones para diagnostico, prevencion y tratamiento de la progresion de los tumores.

Info

Publication number
ES2147646T3
ES2147646T3 ES96911511T ES96911511T ES2147646T3 ES 2147646 T3 ES2147646 T3 ES 2147646T3 ES 96911511 T ES96911511 T ES 96911511T ES 96911511 T ES96911511 T ES 96911511T ES 2147646 T3 ES2147646 T3 ES 2147646T3
Authority
ES
Spain
Prior art keywords
progression
diagnosis
tumors
prevention
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96911511T
Other languages
English (en)
Inventor
Andrew W Shyjan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23632952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2147646(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2147646T3 publication Critical patent/ES2147646T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A METODOS Y COMPOSICIONES PARA EL DIAGNOSTICO, PREVENCION Y TRATAMIENTO DE LA PROGRESION DE TUMORES EN CELULAS IMPLICADAS EN TUMORES HUMANOS TALES COMO MELANOMAS, DE PECHO, GASTROINTESTINALES, TUMORES PULMONARES Y ESTADOS DE NEOPLASIA TALES COMO LEUCEMIAS Y LINFOMAS. SE HAN IDENTIFICADO GENES QUE SE EXPRESAN DIFERENCIALMENTE EN CELULAS TUMORALES BENIGNAS (ESTO ES, NO MALIGNAS) RESPECTO A CELULAS TUMORALES MALIGNAS QUE EXHIBEN UN ELEVADO POTENCIAL METASTASICO. SE IDENTIFICAN ASIMISMO GENES A TRAVES DE LA CAPACIDAD DE SUS PRODUCTOS GENICOS IMPLICADOS EN LA PROGRESION A, Y/O EN LA AGRESIVIDAD DE, ESTADOS DE ENFERMEDAD POR TUMOR NEOPLASICO.
ES96911511T 1995-03-29 1996-03-29 Composiciones para diagnostico, prevencion y tratamiento de la progresion de los tumores. Expired - Lifetime ES2147646T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/412,431 US5633161A (en) 1995-03-29 1995-03-29 Murine gene fomy030 coding for tumor progression inhibitor

Publications (1)

Publication Number Publication Date
ES2147646T3 true ES2147646T3 (es) 2000-09-16

Family

ID=23632952

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96911511T Expired - Lifetime ES2147646T3 (es) 1995-03-29 1996-03-29 Composiciones para diagnostico, prevencion y tratamiento de la progresion de los tumores.

Country Status (11)

Country Link
US (5) US5633161A (es)
EP (3) EP1006187B1 (es)
AT (2) ATE190982T1 (es)
AU (1) AU708746B2 (es)
CA (1) CA2216717C (es)
DE (2) DE69607332T2 (es)
DK (1) DK0817792T3 (es)
ES (1) ES2147646T3 (es)
GR (1) GR3033478T3 (es)
PT (1) PT817792E (es)
WO (1) WO1996030389A1 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US6794185B1 (en) 1995-03-29 2004-09-21 Millennium Pharmaceuticals, Inc. fohy030 nucleic acid molecules
US6251597B1 (en) 1996-03-29 2001-06-26 Millennium Pharmaceuticals, Inc. Methods for detecting fohy030
US6825320B1 (en) 1995-03-29 2004-11-30 Millenium Pharmaceuticals, Inc. FOHY03 polypeptides
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1997018454A2 (en) * 1995-11-16 1997-05-22 Baylor College Of Medicine Method for identifying metastatic sequences
US5783182A (en) * 1996-01-30 1998-07-21 Baylor College Of Medicine Method for identifying metastatic sequences
USRE38490E1 (en) 1995-11-16 2004-04-06 Baylor College Of Medicine Method for identifying metastatic sequences
USRE38392E1 (en) 1996-01-30 2004-01-20 Baylor College Of Medicine Method for identifying metastatic sequences
US6312909B1 (en) 1996-03-29 2001-11-06 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis prevention and treatment of tumor progression
DE69635526T2 (de) * 1996-07-31 2006-08-17 Urocor, Inc., Oklahoma City Biomarker und ziele für die diagnose, prognose und handhabung von prostatkrebs
CA2744096C (en) * 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO1998020143A1 (en) * 1996-11-05 1998-05-14 Abbott Laboratories Reagents and methods useful for detecting diseases of the lung
WO1998033926A1 (en) * 1997-01-31 1998-08-06 Abbott Laboratories Reagents and methods useful for detecting diseases of the lung
WO1998044133A1 (en) * 1997-03-31 1998-10-08 Abbott Laboratories Reagents and methods useful for detecting diseases of the gastrointestinal tract
US6194152B1 (en) 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
ZA989497B (en) * 1997-10-20 2000-04-19 Roche Diagnostics Gmbh Positive-negative selection in homologous recombination.
CA2308565A1 (en) 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
ID27813A (id) * 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
EP1062340A2 (en) 1998-03-13 2000-12-27 The Baylor College of Medicine Compositions and methods for the treatment and prevention of metastatic disorders
EP1792988A3 (en) * 1998-03-18 2007-08-22 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
WO1999047674A2 (en) * 1998-03-18 1999-09-23 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6482597B1 (en) 1999-12-17 2002-11-19 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6312695B1 (en) 1998-03-18 2001-11-06 Corixa Corporation Compounds and methods for therapy of lung cancer
US6696247B2 (en) 1998-03-18 2004-02-24 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6426072B1 (en) 2000-08-02 2002-07-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6821518B1 (en) 1998-03-18 2004-11-23 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6531315B1 (en) 1998-03-18 2003-03-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6518256B1 (en) 1998-03-18 2003-02-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7049063B2 (en) 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6660838B1 (en) 1998-03-18 2003-12-09 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6324479B1 (en) * 1998-05-08 2001-11-27 Rosetta Impharmatics, Inc. Methods of determining protein activity levels using gene expression profiles
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US7258973B2 (en) * 1998-08-31 2007-08-21 Mayo Foundation For Medical Education & Research Method for detecting a differentially expressed sequence
AU6263999A (en) * 1998-09-28 2000-04-17 Chiron Corporation Human genes and gene expression products
ATE386804T1 (de) 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
CA2356286C (en) * 1998-12-23 2010-12-21 University Of Sydney An assay to detect a binding partner
US6156515A (en) * 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
FR2790960B1 (fr) * 1999-03-15 2002-10-31 Pf Medicament Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant
HK1049848A1 (zh) * 1999-04-02 2003-05-30 科里克萨有限公司 用於治療和診斷肺癌的化合物和方法
EP1173570A2 (en) * 1999-04-23 2002-01-23 Corixa Corporation Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma
US20030045468A1 (en) * 1999-05-28 2003-03-06 Corixa Corporation Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
US6470277B1 (en) 1999-07-30 2002-10-22 Agy Therapeutics, Inc. Techniques for facilitating identification of candidate genes
US6720173B1 (en) 1999-11-08 2004-04-13 Lexicon Genetics Incorporated Human kinase protein and polynucleotides encoding the same
WO2001032870A1 (en) * 1999-11-01 2001-05-10 Lexicon Genetics Incorporated Novel human melastatin-like proteins and polynucleotides encoding the same
EP1274463A2 (en) * 1999-12-10 2003-01-15 Whitehead Institute For Biomedical Research Metastasis genes and uses thereof
CA2396127A1 (en) * 1999-12-29 2001-07-12 Torben F. Orntoft Gene expression in biological conditions
EP1276879A4 (en) * 2000-04-11 2004-12-22 Univ Jefferson MUIR-TORRE-LIKE SYNDROME IN Fhit-DEFECTIVE MICE
AU2001270478A1 (en) * 2000-06-30 2002-01-14 Aros Applied Biotechnology Aps Gene expression in biological conditions
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
EP1184457A1 (en) * 2000-09-05 2002-03-06 Warner-Lambert Company Identification of a capacitative calcium channel in antigen presenting cells and uses thereof
EP1186661A1 (en) * 2000-09-05 2002-03-13 Warner-Lambert Company Identification of the major capacitative calcium channel in antigen presenting cells and uses thereof
DE60139705D1 (de) * 2000-11-09 2009-10-08 Sicel Technologies Inc In-vivo detektion von biomolekülekonzentrationen mittels fluoreszenzmarker
MXPA03004579A (es) * 2000-11-28 2003-09-04 Wyeth Corp Analisis de expresion de acidos nucleicos del regulador de cromatina dependiente de actina y polipeptidos utiles en diagnostico y tratamiento del cancer de prostata.
EP2316976A1 (en) * 2000-11-28 2011-05-04 Wyeth LLC Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US7037652B2 (en) * 2000-11-28 2006-05-02 Wyeth Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
US7247426B2 (en) 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20050095588A1 (en) * 2001-10-29 2005-05-05 Kai Wang Process for identifying membrane protein drug targets
US7557353B2 (en) * 2001-11-30 2009-07-07 Sicel Technologies, Inc. Single-use external dosimeters for use in radiation therapies
US7133547B2 (en) * 2002-01-24 2006-11-07 Tripath Imaging, Inc. Method for quantitative video-microscopy and associated system and computer software program product
US7462491B2 (en) * 2002-01-31 2008-12-09 Baylor College Of Medicine Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin
US20030224464A1 (en) * 2002-01-31 2003-12-04 Baylor College Of Medicine Secreted caveolin as a marker for prostate cancer
WO2004075032A2 (en) * 2003-02-19 2004-09-02 Sicel Technologies Inc. In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes
EP2003196A3 (en) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
US20050075543A1 (en) * 2003-10-03 2005-04-07 Calabrese Charles A. Method of anonymous medical testing and providing the patient with the test results
US20050202407A1 (en) * 2003-12-01 2005-09-15 Baylor College Of Medicine Methods and assays for screening anti-neoplastic therapeutic agents
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
EP1717320A1 (en) * 2005-04-26 2006-11-02 TopoTarget Germany AG Identification of human gene sequences of cancer antigens expressed in metastatic carcinoma and involved in metastasis formation, and their use in cancer diagnosis, prognosis and therapy
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
PT2500360E (pt) 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
WO2008092002A2 (en) * 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US7669883B2 (en) * 2007-03-29 2010-03-02 Newfrey Llc Air bag bracket/fastener
ES2663536T3 (es) 2008-09-26 2018-04-13 Oncomed Pharmaceuticals, Inc. Agentes que se unen a receptores frizzled y usos de los mismos
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
HK1212216A1 (en) 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
GB201520550D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203970A1 (en) * 1984-11-30 1986-12-10 Whitehead Institute For Biomedical Research Transmissible, mammalian genes associated with tumor metastasis
US5470970A (en) * 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
WO1992015602A1 (en) * 1991-02-28 1992-09-17 Dana-Farber Cancer Institute, Inc. Cancer diagnosis and therapy
US5262321A (en) * 1991-05-31 1993-11-16 Dana-Farber Cancer Institute DNA encoding p107 tumor suppressor
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
EP0583050A3 (en) 1992-04-29 1994-10-05 Amgen Inc Stimulating factor of the recombinant "neu" receptor.
US5491064A (en) * 1992-07-17 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services HTS-1 gene, a human tumor suppressor gene
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5457049A (en) * 1993-08-12 1995-10-10 Temple University - Of The Commonwealth System Of Higher Education Tumor suppressor protein pRb2, related gene products, and DNA encoding therefor
JP3541966B2 (ja) * 1994-08-03 2004-07-14 東洋紡績株式会社 ポリベンザゾール繊維不織布の製造方法
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US5710137A (en) * 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype

Also Published As

Publication number Publication date
EP1006187A3 (en) 2000-06-21
AU5437896A (en) 1996-10-16
DE69607332T2 (de) 2000-11-30
EP1006187B1 (en) 2003-09-24
GR3033478T3 (en) 2000-09-29
US5674739A (en) 1997-10-07
EP0817792A1 (en) 1998-01-14
WO1996030389A1 (en) 1996-10-03
CA2216717A1 (en) 1996-10-03
EP0817792B1 (en) 2000-03-22
CA2216717C (en) 2010-05-18
US6372896B1 (en) 2002-04-16
PT817792E (pt) 2000-08-31
ATE250624T1 (de) 2003-10-15
EP1006187A2 (en) 2000-06-07
DK0817792T3 (da) 2000-07-31
US5633161A (en) 1997-05-27
DE69630153D1 (de) 2003-10-30
EP0817792A4 (en) 1998-07-01
DE69630153T2 (de) 2004-06-09
EP1344825A1 (en) 2003-09-17
US6025137A (en) 2000-02-15
DE69607332D1 (de) 2000-04-27
US20050106600A1 (en) 2005-05-19
AU708746B2 (en) 1999-08-12
ATE190982T1 (de) 2000-04-15

Similar Documents

Publication Publication Date Title
ES2147646T3 (es) Composiciones para diagnostico, prevencion y tratamiento de la progresion de los tumores.
DE69839682D1 (de) Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von nicht-Hodgkihn-Lymphome
DE3689363D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung der Metastasen von Krebstumoren.
SI1581812T1 (sl) Sestavki in postopki za diagnosticiranje in zdravljenje raka kolona
CA2259936A1 (en) Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
EP0982301A3 (en) Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
ATE262515T1 (de) Discodermolide verbindungen und deren pharmazeutische zusammensetzungen zur krebstherapie
YU21401A (sh) Tetrahidropiridoetri
MY130544A (en) Antineoplastic use and pharmaceutical compositions containing them
WO2000055629A3 (en) Methods of diagnosing and treating breast cancer
TR199903154T2 (xx) Meme kanserinin tedavisi ve te�hisi i�in bile�imler ve y�ntemler
DK0767786T3 (da) 7-ether-taxol-analoge, antineoplastisk anvendelse deraf og farmaceutiske præparater indeholdende disse forbindelser
ATE265455T1 (de) Tetrahydropyridoverbindungen
DE60234930D1 (en) Farbstoff-sulfenate für die duale phototherapie
SE7706526L (sv) Forfarande for framstellnilng av 3-(3-karboxi-4-hydroxifenyl)-4,5-dihydro-2-fenylbens/e/indol och dermed beslektade verdefulla mellanforeningar
EP1107006A4 (en) METHOD FOR DIAGNOSING BONE METASTASES AND MALIGNING TUMORS
EP1953243A3 (en) Polynucleotides related to colon cancer
WO1991019725A3 (en) Heterocyclic anthracyclione and anthracycline analogs
ATE397673T1 (de) Verstärktes krebs-gen wip1
MX9100290A (es) Compuestos de antraceno utiles farmaceuticamente.
SHIRAISHI et al. A CASE OF SIMULTANEOUS MALE BREAST AND ESOPHAGEAL CANCER
WO2003018769A3 (en) Amplified gene involved in cancer
WO2002021134A3 (en) Methods of diagnosing breast cancer and screening for modulators
RU92016483A (ru) Аналоги гетероциклических антрациклинов и антрациклионов
MX9709683A (es) Uso de derivados de vitamina d4 para tratamiento contra el cancer.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 817792

Country of ref document: ES